Eli Lilly and Company (BVMF:LILY34)

Market Cap	4.95T +21.1%
Revenue (ttm)	359.01B +44.7%
Net Income	113.69B +94.9%
EPS	126.41 +96.0%
Shares Out	n/a
PE Ratio	43.50
Forward PE	30.68
Dividend	0.75 (0.41%)
Ex-Dividend Date	Nov 13, 2025

Volume	4,400
Average Volume	20,080
Open	184.60
Previous Close	179.99
Day's Range	179.99 - 185.59
52-Week Range	113.00 - 208.36
Beta	0.39
RSI	48.22
Earnings Date	Feb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: LILY34

Financial Performance

In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.

Financial numbers in USD